Inotuzumab ozogamicin
Based on 1 Customer Validation
Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22+ B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia.
For research use only. We do not sell to patients.
- Purity: 99.7%
- CAS No.: 635715-01-4
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG2 kappa
Human
Kd ≈ 150 pM (CD22)[1]
Inotuzumab ozogamicin exerts highly potent cytotoxic activity against a vari-
ety of CD22-positive B-cell origin cancer cell lines[1].
Inotuzumab ozogamicin and G544
bind human CD22 with similar affinities (KD ≈ 150 pM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 635715-01-4
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Inotuzumab ozogamicin]
-
Synonyms
CMC-544; PF-5208773; WAY-207294
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Shor B, et al. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2 Pt A):107-116. [Content Brief]
[2]. Kantarjian H, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403-411. [Content Brief]
[3]. Advani A, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085-2093. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Inotuzumab ozogamicin Related Classifications
HY-P9959 Related Classifications
Powered by Bioz
- Inotuzumab ozogamicin
- 635715-01-4
- CMC-544
- PF-5208773
- WAY-207294
- CMC544
- CMC 544
- PF5208773
- PF 5208773
- PF-5208773
- WAY207294
- WAY 207294
- WAY-207294
- Antibody-Drug Conjugates (ADCs)
- CD22
- B-cell malignancy models
- diffuse large B-cell lymphoma
- non-Hodgkin’s lymphoma
- apoptosis
- calicheamicin
- DNA double-strand breaks
- B-cell
- follicular lymphoma
- acute lymphocytic leukemia
- Inhibitor
- inhibitor
- inhibit